Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies
- 1 July 2007
- journal article
- antiretroviral drug-toxicity
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 2 (4) , 282-292
Abstract
Purpose of review To describe the clinical features, pathogenesis and therapeutic options for the dyslipidaemia commonly seen in HIV-infected patients on combination antiretroviral therapy. Recent findings Dyslipidaemia associated with antiretroviral therapy is characterized by elevations in total and low-density lipoprotein-cholesterol and triglycerides, and decreased high-density lipoprotein-cholesterol – a profile with atherogenic potential. Although a multifactorial cause underlies antiretroviral therapy-associated dyslipidaemia, exposure to all three principal classes of antiretroviral medications – protease inhibitors in particular – has been implicated in its development. Protease inhibitors have been shown to affect several molecular pathways important for lipid metabolism, including intranuclear transcription factors and the nuclear proteasome. Although treatment options are limited, with many conventional therapeutic strategies less effective in the presence of ongoing antiretroviral therapy exposure, the increased incidence of cardiovascular disease observed in some HIV-infected cohorts underlies the need for effective management strategies for antiretroviral therapy-associated dyslipidaemia. Summary Although use of protease inhibitors is implicated in antiretroviral therapy-associated dyslipidaemia, the extent to which individual protease inhibitors cause dyslipidaemia varies considerably within this drug class. More research is needed to design better tolerated antiretrovirals and improved therapeutic interventions for this common condition.Keywords
This publication has 78 references indexed in Scilit:
- Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Familial DyslipidaemiasDrugs, 2006
- Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backboneHIV Medicine, 2005
- Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected AdultsNew England Journal of Medicine, 2005
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Impact of HIV Infection and HAART on Serum Lipids in MenJAMA, 2003
- Relationship Between HAART Adherence and Adipose Tissue AlterationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Alterations of Apolipoprotein B Metabolism in HIV-Infected Patients With Antiretroviral Combination TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndromeEuropean Journal of Internal Medicine, 2000